



Divi's Laboratories Limited

Regd. Office: 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad - 500032. CIN: L24110TG1990PLC011854
Phone: 040-23786300 Fax: 040-23786460 email: mail@divislabs.com website: www.divislabs.com

Statement of Standalone & Consolidated Audited Financial Results for the Quarter and Year Ended 31st March, 2018

(₹ in Lakhs)

Particulars	STANDALONE					CONSOLIDATED	
	QUARTER ENDED		YEAR ENDED			YEAR ENDED	
	31.03.2018 (Audited)	31.12.2017 (Unaudited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)
Total Revenue from operations	113612	105489	108757	394971	414172	402622	418115
Net Profit / (Loss) for the period (before Tax and Exceptional items)	39605	30550	35045	121936	138823	123133	139534
Net Profit / (Loss) for the period before tax (after Exceptional items)	39605	30550	35045	121936	138823	123133	139534
Net Profit / (Loss) for the period after tax (after Exceptional items)	26160	22466	25929	86958	105327	87701	106042
Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax)]	26338	22429	25949	87025	105187	88691	106409
Equity Share Capital	5309	5309	5309	5309	5309	5309	5309
Other Equity				590656	535582	587171	530430
Earnings Per Share (of ₹ 2/- each) (not annualised) Basic & Diluted (₹)	9.85	8.46	9.77	32.76	39.68	33.04	39.95

Notes:

- The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/ Annual Financial Results are available on the Stock Exchanges Websites (www.bseindia.com and www.nseindia.com) and also available on the Company's website www.divislabs.com.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Board of Directors of the company has recommended a dividend of Rs.10/- per equity share of Rs.2 each (i.e., 500%), subject to approval of members.
- The company's Unit-II at Visakhapatnam was inspected by the US-FDA during September, 2017. This inspection was for full cGMP and verification of all corrective actions proposed against the previous inspection observations. All previous observations have been confirmed as completed and resolved. Subsequently, the US-FDA has issued Establishment Inspection Report (EIR) for the Unit-II as a closure of the audit.
- The company's Unit-I at Choutuppal, Telangana State has also been inspected by the US-FDA during May 2018. This was a general cGMP inspection by the FDA and the inspection was concluded without any observations.

for Divi's Laboratories Limited

Place : Hyderabad
Date : 26.05.2018

Dr. Murali K. Divi
Chairman & Managing Director